|
EP3772511A1
|
|
Process for the preparation of a nitric oxide donating prostaglandin analogue
|
|
CA3108551A1
|
|
Nitric oxide releasing phosphodiesterase type 5 inhibitor
|
|
KR20210032435A
|
|
Ophthalmic composition containing nitric oxide-releasing prostamide
|
|
WO2019121488A1
|
|
Nitric oxide releasing hyaluronic esters
|
|
WO2018224419A1
|
|
Nitric oxide donating isomannide derivatives
|
|
EP3757089A1
|
|
Process for the preparation of a nitric oxide donating prostaglandin analogue
|
|
WO2016156104A1
|
|
Nitric oxide donating derivatives of latanoprost free acid
|
|
US2018118677A1
|
|
Nitric oxide donating derivatives of fluprostenol
|
|
CN106999452A
|
|
The combination product of prostanoid and nitric oxide donors
|
|
EP3088388A1
|
|
Nitric oxide donating derivatives of prostaglandins
|
|
WO2015110430A1
|
|
Ophthalmic compositions comprising iota-carrageenan
|
|
US2014135389A1
|
|
Quinone based nitric oxide donating compounds
|
|
EP2911656A1
|
|
Quinone based nitric oxide donating compounds for ophthalmic use
|
|
US2013137765A1
|
|
Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
|
|
CA2839390A1
|
|
Quinone based nitric oxide donating compounds
|
|
WO2012152438A1
|
|
Process for the preparation of nitrate acid ester of organic compounds
|
|
WO2011101245A1
|
|
Nitric oxide releasing compounds for the treatment of neuropathic pain
|
|
WO2011092065A1
|
|
Nitric oxide releasing compounds for the treatment of neurophatic pain
|
|
WO2010118968A1
|
|
No-donor aspirin derivatives
|
|
US2010240745A1
|
|
Method of treatment of inflammation in hypertensive patients
|
